GlassScriptPhysician profile
Michael David Carletti
NPI 1013126390
$44,316.17
in general payments reported to CMS, 2019-2025
43 companies · $11K in 2025
The $11K reported for 2025 was more than what 92% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,978 · 2020: $2,926 · 2021: $3,960 · 2022: $6,152 · 2023: $7,528 · 2024: $8,226 · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $22K · Consulting Fee: $3,488 · Education: $363.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $22,448.78 |
| Consulting Fee | $3,487.50 |
| Education | $363.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $7,644.34 | 2019-2025 | Rinvoq, Skyrizi |
| Janssen Biotech, INC. | $6,546.58 | 2019-2025 | Tremfya, Stelara, Simponi |
| Novartis Pharmaceuticals Corporation | $4,051.02 | 2019-2025 | |
| Lilly USA, LLC | $3,194.89 | 2019-2025 | Olumiant, Taltz, Ebglyss |
| Sun Pharmaceutical Industries INC. | $2,684.75 | 2020-2025 | Ilumya, Winlevi, Blu-U |
| Genzyme Corporation | $2,464.86 | 2019-2025 | |
| Amgen INC. | $2,447.09 | 2019-2025 | Otezla, Otezla |
| Pfizer INC. | $1,583.10 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $1,273.84 | 2019-2025 | Dupixent, Libtayo |
| Dermavant Sciences, INC. | $1,220.90 | 2022-2024 | Vtama |
| Galderma Laboratories, L.P. | $1,016.64 | 2019-2025 | Nemluvio, Aklief, Epsolay |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $1,008.05 | 2019-2025 | Arazlo, Targretin, Cabtreo |
| Janssen Scientific Affairs, LLC | $980.18 | 2021-2025 | Tremfya |
| Ucb, INC. | $957.07 | 2022-2025 | Bimzelx, Cimzia |
| Incyte Corporation | $827.91 | 2021-2025 | Opzelura |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Carletti listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.